VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma

Annemiek Broijl; Augustinus C M de Jong; Mark van Duin; Pieter Sonneveld; Jesper Kühnau; Vincent H J van der Velden

doi:10.1093/ajcp/aqab163

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma

Annemiek Broijl, Augustinus C M de Jong, Mark van Duin, Pieter Sonneveld, Jesper Kühnau, Vincent H J van der Velden^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

46 Downloads (Pure)

Abstract

OBJECTIVES: To compare flow cytometric minimal residual disease (MRD) data obtained using the EuroFlow approach, including the CD38-multiepitope (ME) antibody or the VS38c antibody.

METHODS: We evaluated 29 bone marrow samples from patients with multiple myeloma (MM), of whom 15 had received daratumumab within the past 6 months. We evaluated MRD data and fluorescence intensities.

RESULTS: Qualitative MRD data were 100% concordant between the 2 approaches. In MRD-positive samples (n = 14), MRD levels showed an excellent correlation (R2 = 0.999). Whereas VS38c staining was strong in both normal plasma cells and MM cells, independent of daratumumab treatment, staining intensities for CD38 were lower in MM cells compared with normal plasma cells, and on both cell types CD38 expression was significantly reduced in daratumumab-treated patients.

CONCLUSIONS: Both CD38-ME and VS38c allow reliable MRD detection in MM patients, but the high expression of VS38c allows easier identification of MM cells, especially in daratumumab-treated patients.

Original language	English
Pages (from-to)	494-497
Number of pages	4
Journal	American Journal of Clinical Pathology
Volume	157
Issue number	4
DOIs	https://doi.org/10.1093/ajcp/aqab163
Publication status	Published - 1 Apr 2022

Bibliographical note

Funding Information:
This work was supported by a nonrestrictive grant from Agilent Technologies

Publisher Copyright:
© 2021 American Society for Clinical Pathology, 2021.

Access to Document

10.1093/ajcp/aqab163Licence: CC BY-NC

aqab163Final published version, 648 KBLicence: CC BY-NC

Cite this

@article{df7eb401bd344d20b4b7eb3059d0a53d,

title = "VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma",

abstract = "OBJECTIVES: To compare flow cytometric minimal residual disease (MRD) data obtained using the EuroFlow approach, including the CD38-multiepitope (ME) antibody or the VS38c antibody.METHODS: We evaluated 29 bone marrow samples from patients with multiple myeloma (MM), of whom 15 had received daratumumab within the past 6 months. We evaluated MRD data and fluorescence intensities.RESULTS: Qualitative MRD data were 100% concordant between the 2 approaches. In MRD-positive samples (n = 14), MRD levels showed an excellent correlation (R2 = 0.999). Whereas VS38c staining was strong in both normal plasma cells and MM cells, independent of daratumumab treatment, staining intensities for CD38 were lower in MM cells compared with normal plasma cells, and on both cell types CD38 expression was significantly reduced in daratumumab-treated patients.CONCLUSIONS: Both CD38-ME and VS38c allow reliable MRD detection in MM patients, but the high expression of VS38c allows easier identification of MM cells, especially in daratumumab-treated patients.",

author = "Annemiek Broijl and {de Jong}, {Augustinus C M} and {van Duin}, Mark and Pieter Sonneveld and Jesper K{\"u}hnau and {van der Velden}, {Vincent H J}",

note = "Funding Information: This work was supported by a nonrestrictive grant from Agilent Technologies Publisher Copyright: {\textcopyright} 2021 American Society for Clinical Pathology, 2021.",

year = "2022",

month = apr,

day = "1",

doi = "10.1093/ajcp/aqab163",

language = "English",

volume = "157",

pages = "494--497",

journal = "American Journal of Clinical Pathology",

issn = "0002-9173",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma

AU - Broijl, Annemiek

AU - de Jong, Augustinus C M

AU - van Duin, Mark

AU - Sonneveld, Pieter

AU - Kühnau, Jesper

AU - van der Velden, Vincent H J

PY - 2022/4/1

Y1 - 2022/4/1

N2 - OBJECTIVES: To compare flow cytometric minimal residual disease (MRD) data obtained using the EuroFlow approach, including the CD38-multiepitope (ME) antibody or the VS38c antibody.METHODS: We evaluated 29 bone marrow samples from patients with multiple myeloma (MM), of whom 15 had received daratumumab within the past 6 months. We evaluated MRD data and fluorescence intensities.RESULTS: Qualitative MRD data were 100% concordant between the 2 approaches. In MRD-positive samples (n = 14), MRD levels showed an excellent correlation (R2 = 0.999). Whereas VS38c staining was strong in both normal plasma cells and MM cells, independent of daratumumab treatment, staining intensities for CD38 were lower in MM cells compared with normal plasma cells, and on both cell types CD38 expression was significantly reduced in daratumumab-treated patients.CONCLUSIONS: Both CD38-ME and VS38c allow reliable MRD detection in MM patients, but the high expression of VS38c allows easier identification of MM cells, especially in daratumumab-treated patients.

AB - OBJECTIVES: To compare flow cytometric minimal residual disease (MRD) data obtained using the EuroFlow approach, including the CD38-multiepitope (ME) antibody or the VS38c antibody.METHODS: We evaluated 29 bone marrow samples from patients with multiple myeloma (MM), of whom 15 had received daratumumab within the past 6 months. We evaluated MRD data and fluorescence intensities.RESULTS: Qualitative MRD data were 100% concordant between the 2 approaches. In MRD-positive samples (n = 14), MRD levels showed an excellent correlation (R2 = 0.999). Whereas VS38c staining was strong in both normal plasma cells and MM cells, independent of daratumumab treatment, staining intensities for CD38 were lower in MM cells compared with normal plasma cells, and on both cell types CD38 expression was significantly reduced in daratumumab-treated patients.CONCLUSIONS: Both CD38-ME and VS38c allow reliable MRD detection in MM patients, but the high expression of VS38c allows easier identification of MM cells, especially in daratumumab-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=85126439685&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqab163

DO - 10.1093/ajcp/aqab163

M3 - Article

C2 - 34643211

SN - 0002-9173

VL - 157

SP - 494

EP - 497

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

IS - 4

ER -

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this